Therefore, a deeper understanding of the immunomodulatory effects of PI3K/AKT/mTOR inhibitors may pave the way for their efficient combination with other therapeutic agents, including immune checkpoint blockers, to enhance clinical outcomes for patients with ARID1A‐deficient cancers. The gene discussed is ARID1A; the disease is cancer.